Meropenem Pharmacenter (Meropenem Anhydrous)

Meropenem is indicated for serious infections caused by susceptible bacteria, particularly in hospital‑acquired settings.

• Complicated intra‑abdominal infections: provides broad coverage against aerobic and anaerobic pathogens, facilitating infection control after surgical intervention.
• Complicated urinary tract infections: eradicates resistant Gram‑negative organisms, aiding resolution of pyelonephritis and cystitis.
• Hospital‑acquired bacterial pneumonia, including ventilator‑associated pneumonia: achieves bacterial clearance in severe pulmonary infections.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat acute meningitis caused by susceptible strains.
• Septicemia and febrile neutropenia: delivers rapid bactericidal activity in systemic infections.

• Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins (PBPs) on the bacterial cell wall. This inhibits the final transpeptidation step of peptidoglycan synthesis, weakening the cell wall and leading to osmotic lysis. Its high affinity for a broad range of PBPs, including those of resistant Gram‑negative organisms, underlies its potent, time‑dependent bactericidal activity. The drug remains stable against most β‑lactamases, allowing it to retain activity where other β‑lactams fail.

Meropenem may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Diarrhea: mild to moderate loose stools.
• Nausea: transient feeling of queasiness.
• Rash: non‑specific skin eruption.
• Elevated liver enzymes: transient increase in ALT/AST.
• Headache: mild to moderate intensity.
• Infusion site phlebitis: local irritation at IV site.
• Fever: drug‑induced pyrexia.
• Vomiting: occasional upset stomach.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: antibiotic‑associated diarrhea.
• Hemolytic anemia: immune‑mediated red cell destruction.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Thrombocytopenia: reduced platelet count.
• Hypotension: sudden drop in blood pressure during infusion.
• Elevated creatinine: renal function changes.

When using Meropenem, clinicians should observe several precautionary measures to minimize risks and ensure optimal therapy.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Monitor for neurotoxicity: observe for seizures or altered mental status, especially in the elderly.
• Allergy screening: avoid use in individuals with known hypersensitivity to β‑lactam antibiotics.
• Concomitant nephrotoxic drugs: use caution when combined with aminoglycosides or vancomycin.
• Therapeutic drug monitoring: consider plasma level checks in severe infections or renal dysfunction.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Valproic acid: concurrent use may reduce serum valproate levels, risking seizure breakthrough.
• Carbapenem‑induced reduction of oral contraceptives: may diminish hormonal contraceptive effectiveness.

Moderate Interactions (Monitor Closely)

• Aminoglycosides (e.g., gentamicin): increased risk of nephrotoxicity when combined.
• Loop diuretics (e.g., furosemide): may enhance renal toxicity.
• Anticoagulants (e.g., warfarin): monitor INR as carbapenems can alter coagulation parameters.